Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Janice C. Parker"'
Autor:
Judith L. Treadway, David W. Piotrowski, R. Kirk McPherson, Jana Polivkova, Anne M. Brodeur, Shenping Liu, Bernard Hulin, David D. Boyer, Stephen J. Orena, Xiayang Qiu, Maria A. Vanvolkenburg, Dennis E. Danley, Donald C. Wilder, Janice C. Parker, Shawn D. Doran, Carolyn B. Soglia, Mark Ammirati, Kim M. Andrews
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 19:1991-1995
A series of 4-substituted proline amides was synthesized and evaluated as inhibitors of dipeptidyl pepdidase IV for the treatment of type 2 diabetes. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fb8cf65715687f0bc8ee1e7e04655a6
https://doi.org/10.1016/j.bmcl.2009.02.041
https://doi.org/10.1016/j.bmcl.2009.02.041
Autor:
Hong Wang, Judith L. Treadway, Maria A. Vanvolkenburg, Anne M. Brodeur, L. D. Mcclure, Shawn D. Doran, Jay S. Lillquist, Kim M. Andrews, Stephen J. Orena, Stephen W. Wright, Donald C. Wilder, Jana Polivkova, R. Kirk McPherson, Mark Ammirati, Janice C. Parker, Thanh V. Olson, Walter C. Soeller, Xiayang Qiu, Carolyn B. Soglia, Dennis E. Danley
Publikováno v:
Journal of Medicinal Chemistry. 49:3068-3076
Inhibitors of the glucagon-like peptide-1 (GLP-1) degrading enzyme dipeptidyl peptidase IV (DPP-IV) have been shown to be effective treatments for type 2 diabetes in animal models and in human subjects. A novel series of cis-2,5-dicyanopyrrolidine al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7225566352cae2523ca6fd2fce0bf4d9
https://doi.org/10.1021/jm0600085
https://doi.org/10.1021/jm0600085
Autor:
Shawn Cabral, Michael G. Lopaze, Kim M. Andrews, Bernard Hulin, Janice C. Parker, Maria A. Van Volkenburg
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 15:4770-4773
Cyclohexylglycine amides of various fluorinated pyrrolidines and azetidines were prepared and tested for activity against dipeptidyl peptidase IV and in vivo in the KK mouse model of type 2 diabetes. The tetrafluoropyrrolidide, cis-3,4-difluoropyrrol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c047923db443ffb8ad2110e6efeaafa9
https://doi.org/10.1016/j.bmcl.2005.07.026
https://doi.org/10.1016/j.bmcl.2005.07.026
Autor:
Toshiyuki Saito, Taisuke Inagaki, Hiroko Tonai-Kachi, Yoshinao Kato, Shinichi Sakemi, Nakao Kojima, Toshio Ichiba, Hiroyuki Nishida, Hideo Hirai, Janice C. Parker, Yasuhiro Kojima, Maria A. Vanvolkenburg, Nobuji Yoshikawa
Publikováno v:
The Journal of Antibiotics. 55:941-951
High-throughput screening of microbial extracts using rat hepatic microsomal glucose-6-phosphatase (G6Pase) led us to find thielavin B as a G6Pase inhibitor with inhibition of glucose output from glucagon-stimulated hepatocytes. Further searching for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52af041ad2674ec95c9b65f9138fcfa2
https://doi.org/10.7164/antibiotics.55.941
https://doi.org/10.7164/antibiotics.55.941
Autor:
T G Gant, Y Kwon, Judith L. Treadway, P A Carpino, Maria A. Vanvolkenburg, S H Burk, Janice C. Parker, P Vestergaard, Carolyn B. Levy, William H. Martin, R K McPherson, C Giragossian
Publikováno v:
Diabetes. 47:1630-1636
The activity of glucose-6-phosphatase (G-6-Pase) in isolated rat microsomes was inhibited by a new selective inhibitor of the multi-subunit G-6-Pase system, 1-[2-(4-chloro-phenyl)-cyclopropylmethoxy]-3,4-dihydroxy-5-(3-imid azo[4,5-b]pyridin-1-yl-3-p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5897b072415c1657c6474df4fee8faa
https://doi.org/10.2337/diabetes.47.10.1630
https://doi.org/10.2337/diabetes.47.10.1630
Autor:
Maynard D. Carty, Janice C. Parker, Walter C. Soeller, David K. Kreutter, Susan Emeigh Hart, Ralph W. Stevenson, Peter C. Butler, Juliette Janson
Publikováno v:
Diabetes. 47:743-750
We have previously shown that hemizygous transgenic mice expressing human islet amyloid polypeptide (hIAPP) in pancreatic beta-cells have no diabetic phenotype, whereas in the homozygous state, they developed severe, early-onset hyperglycemia associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a6eb3f14167067c48ddf009cf2ba33a
https://doi.org/10.2337/diabetes.47.5.743
https://doi.org/10.2337/diabetes.47.5.743
Publikováno v:
Metabolism. 44:1231-1237
In vitro, truncated glucagon-like peptides [GLP-1(7-36)-amide and GLP-1(7-37)] increase insulin secretion in a glucose-dependent manner, and desensitization to the action of GLP-1(7-37) has been demonstrated acutely with high concentrations. The purp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e94ed7847b8912684ae9ed5e79204906
https://doi.org/10.1016/0026-0495(95)90021-7
https://doi.org/10.1016/0026-0495(95)90021-7
Autor:
Hiroko Tonai-Kachi, Toshiyuki Saito, Maria A. Van Volkenburg, Shinichi Sakemi, Yoon-Jeong Kim, Hiroyuki Nishida, Yasuhiro Kojima, Chang-Hong Pang, Janice C. Parker, Nobuji Yoshikawa
Publikováno v:
ChemInform. 33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28b100c05b7f0604f11ff82e80527bdf
https://doi.org/10.1002/chin.200232237
https://doi.org/10.1002/chin.200232237
Autor:
Maria A. Vanvolkenburg, L. D. Mcclure, Stephen J. Orena, Kim M. Andrews, Benjamin N. Rocke, Jay S. Lillquist, Judith L. Treadway, Stephen W. Wright, Zhengrong Zhao, Thanh V. Olson, Janice C. Parker, Shawn D. Doran, Walter C. Soeller, R. Kirk McPherson, Anne M. Brodeur, Cox Eric David, Carolyn B. Soglia, Shenping Liu, Mark Ammirati, Dennis E. Danley
Publikováno v:
Bioorganicmedicinal chemistry letters. 17(20)
A series of pyrrolidine based inhibitors of dipeptidyl peptidase IV were developed from a high throughput screening hit for the treatment of type 2 diabetes. Potency, selectivity, and pharmacokinetic properties were optimized resulting in the identif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69f927a94060b522e9278cf93b62b98b
https://pubmed.ncbi.nlm.nih.gov/17822893
https://pubmed.ncbi.nlm.nih.gov/17822893
Autor:
Leonard G. Contillo, Janice C. Parker, Ralph W. Stevenson, Glenn C. Andrews, Jane M. Withka, Walter W. Massefski, David H. Singleton, Kim M. Andrews
Publikováno v:
Peptides for the New Millennium ISBN: 0792364457
Glucagon-like peptide-1 (GLP-1) is an effective insulin secretagogue with sustained efficacy, with therapeutic potential in treating diabetes [1], As a result there has been much interest is determining its’ receptor bound conformation for rational
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfa67974d3f033e121416bd35eeac493
https://doi.org/10.1007/0-306-46881-6_267
https://doi.org/10.1007/0-306-46881-6_267
